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ABSTRACT 
ETV6-RUNX1 is the most common chromosomal alteration in pediatric B cell acute 
lymphoblastic leukemia. ETV6-RUNX1 represses RUNX1 target genes. However, little is 
known about the target genes of ETV6-RUNX1 that are involved in promoting 
leukemogenesis. A recent study with two human leukemia cell lines AT-2 and REH, which 
express ETV6-RUNX1, suggested that SPIB was one of the top of the genes that were up 
regulated after knocking down the ETV6-RUNX1 fusion protein. In addition, our lab showed 
that deletion of PU.1 and Spi-B in B cells in mice resulted in the development of B cell acute 
lymphoblastic leukemia with 100% incidence. It is still not clear what pathways and target 
genes are affected by the loss of PU.1 and Spi-B and contribute to leukemogenesis. We 
hypothesized that ETV6-RUNX1 function as an oncogenic driver by repressing SPIB 
transcription, leading to impaired B cell receptor signaling. This hypothesis was divided into 
two parts. First, examining how PU.1 and Spi-B could act as tumor suppressor genes in B 
cells in our mouse model using gene expression profiling. The results of the microarray 
specified impairment in the expression of genes involved in BCR signaling pathways. Second, 
we aimed to determine the molecular mechanism of how SPIB is repressed by ETV6-
RUNX1. ChIP results suggested that ETV6-RUNX1 directly interacts with SPIB. This study 
is expected to lead to a deeper understanding of the underlying biology of leukemogenesis 
caused by the loss of SPIB in ETV6-RUNX1 leukemia patients, hence allowing for the 
development of new molecular targeted therapies for B-cell leukemia.  
Keywords: B cell acute lymphoblastic leukemia, ETV6-RUNX1 B-ALL, PU.1. SPIB, and B 
cell receptor signaling (BCR).
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Chapter1: Introduction 
1.1 Overview: 
B cell development from hematopoietic stem cells (HSC) to mature B cells is a highly 
regulated process. This multi-step process is tightly controlled by the interaction of the 
extrinsic cytokines and B cell receptor signaling (BCR) pathways and intrinsic transcriptional 
programming [1].  Disruption of this balanced interaction could lead in most cases to a block 
in B cell development and death. However, in certain circumstances the disruption might 
reprogram the B cell fate into a new developmental fate. This reprograming occurs in vivo in 
human B cell acute lymphoblastic leukemia (B-ALL). In general, the molecular players 
leading to these aberrant fates have key roles in the normal B cell development [1]. 
 1.1.1 Stages of B cell development:  
The multiple stages of B cell development that fall between HSC and mature B cells have 
been extensively studied [2, 3]. HSCs are identified by their cell surface markers; lineage 
negative (Linneg ) c-kithigh  and Sca-1postive [4]. HSCs are heterogeneous group of cells, which 
include long term HSC and short term HSC. The short term HSCs give rise to the multipotent 
progenitor cells (MPP) [5, 6]. MPP cells share the same phenotype of HSCs. In addition, they 
express Flt3 receptors. The MPP cells have the potential to give rise to two cell 
compartments, which represent two different lineages of cells; the common myeloid 
progenitor (CMP) and the early lymphoid progenitor (ELP) [7, 8]. As the name implies, 
CMP is the transitional compartments from which erythroid and myeloid cells are generated 
[7]. Lymphoid cells are generated from the ELP cells. These cells are characterized by 
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Linnegc-kit high Sca-1pos Flt3 pos IL-7R neg  [8]. Further differentiation of ELP cells to common 
lymphoid progenitor (CLP) cells is characterized by decreased expression of c-kit and Sca-1, 
the acquisition of additional cell surface markers that include the interleukin-7 receptor (IL-
7R) and AA4.1 (CD93), and the increased expression of RAG1/2 [9, 10]. These markers are 
considered hallmarks of further maturation toward B-lymphocytes. CLPs are the first 
progenitor cells that specify B lineage development. CLP cells progeny consist of pre-pro-B, 
pro-B, pre-B, and finally, newly produced sIgMpos B lymphocytes [2]. Pre-pro-B cells are 
characterized by Linneg  CD45Rpos CD43pos  AA4.1pos CD19neg Ly6Cneg [11]. Pro-B cells are 
defined as CD45Rpos CD19pos  CD43pos  AA4.1pos, and are considered the first progeny 
committed toward B cell development [8]. In addition to the cell surface markers, B cell 
stages are defined by the status of immunoglobulin (Ig) gene rearrangement [12, 13]. 
Immunoglobulin heavy chain (IgHC) gene rearrangements occur in CLP, pre-pro-B, and pro-
B cells. If pro-B cells successfully rearrange their Igs, they mature to pre-B cells. In pre-B 
cells, the successful production of immunoglobulin light chain (IgLC) rearrangement results 
in the production of immature B cells (sIgMpos B lymphocytes) that will migrate from the 
bone marrow to the spleen to complete the maturation process [2, 12].    
1.1.2 Transcriptional regulation of B cell commitment: 
 Each stage of B cell development can be defined by the expression of key transcription 
factors [14, 15]. These transcription factors act in complex networks involving cross and auto 
regulation, which lead to the activation of specific target genes involved in B cell maturation 
[16].  The transcription factors PU.1, Ikaros, E2A, EBF, and PAX5 are essential in B cell 
specification and commitment [17-21]. PU.1 and Ikaros are required in the early stages of B 
cell development. They are both expressed in lymphoid primed multipotent progenitor cells 
and promote the expression of FLT3. FLT3 signaling acts with PU.1 to induce the expression 
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of IL-7R. IL-7 signaling acts to induce the transcription factor E2A in CLP. PU.1 and E2A, 
with IL-7 induce the expression of EBF, which is considered a critical event in specification 
of B cell development. CLP will give rise to the pro-B cell where the transcription factor 
PAX5 is expressed. PAX5 functions to promote B cell commitment by reinforcing B cell 
specific gene expression and repressing other lineage gene expression (Figure 1.1) [16].  
1.1.3 Interleukin 7 (IL-7) and Interleukin 7 receptor (IL-7R) in B cell development:   
   IL-7 is a type 1 cytokine, which has a central role in early B cell development that includes 
commitment, survival, proliferation and maturation. IL-7 is mainly secreted by stromal cells 
in the lymphoid tissues [22-24]. The receptor for IL-7 is composed of two chains IL-7Rα 
chain and common γ chain (dimer receptor) [25].  
  Studies have provided evidence for the role of IL-7 in the commitment of the CLP to B cell 
lineage [26]. First, CLP without the presence of IL-7 cannot undergo B cell differentiation 
[26]. Second, as mentioned above, IL-7R signaling induces the expression of E2A. Then 
E2A with PU.1 and IL-7R induce the expression of EBF, which is an important transcription 
factor in B cell commitment [27]. Third, in the presence of IL-7, Pax5 -/- pro-B cells 
maintained their identity as early B cells, where without IL-7 these cells developed a 
macrophage phenotype [28].  
  In support of the notion that IL-7 is required for maturation and proliferation during early B 
cell development, studies with targeted deletions of genes encoding IL-7 or IL-7R in mice, 
showed a block in B cell differentiation at pro-B cell stage with only a few B cells maturing. 
In addition, pro-B cells stimulated with IL-7 undergo robust proliferation [24]. IL-7 signaling 
regulates many proteins involved in cell cycle regulation. N-myc and c-myc are expressed 
when pre-B cells are stimulated with IL-7. Enforced expression of c-myc enhances the 
activity of cyclin dependent kinase (CDK), which stimulates cell cycle progression [29, 30].  
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Figure 1.1 stages of B cell development  
Sequential stages of early B cell differentiation from LMPP to Pre-B cells. Key transcription 
factors, growth factor receptors and cell surface markers of each stage are shown.  
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1.1.4 Pre-B cell receptor signaling in B cell development:  
  Pre-BCR signaling has an important role in proliferation and differentiation of the pre-B 
cells. Pre-BCR receptor expression serves as a checkpoint for successful immunoglobulin 
heavy chain gene rearrangement (IgHC). The successful recombination of the IgHC gene 
encodes for Igµ that associates with the germline-encoded surrogate light chain (SLC), and 
the signaling molecules Igα and Igβ to produce the pre-BCR receptor complex. Once the pre-
BCR complex is on the cell surface, signaling through the receptor leads to robust 
proliferation [31, 32]. This proliferation is mediated through the activation of signaling 
molecules down stream of the pre-BCR receptor. The cytosolic kinase Syk is rapidly 
phosphorylated after the engagement of the pre-BCR receptor. Phosphorylation of Syk leads 
to the activation of the PI3K pathway. PI3K activates the adaptor protein BAM32 and other 
signaling proteins including PKB/AKT. These proteins stimulate cell proliferation and inhibit 
apoptosis [33-35]. In addition to promoting cell proliferation, Syk induces pre-B cell 
differentiation by activating the adaptor molecules B cell linker protein (BLNK) and  
Bruton’s tyrosine kinase (Btk) [36].  
  Once BLNK is activated, it provides docking sites for many signaling molecules such as 
Vav, Btk, Grb2, and PLC-γ2 [36]. Recent studies have shown the role of BLNK in 
transmitting differentiation signals and inhibiting proliferation signals. First, up-regulation of  
pre-BCR surface receptor expression and increased cell proliferation has been shown in Blnk 
deficient pre-B cells. In addition, forced expression of BLNK in these cells resulted in the 
down regulation of pre-BCR surface receptor and enhanced pre-B cell differentiation. 
Second, many studies have illustrated the negative effect of BLNK on IL-7R signaling 
through different mechanisms [37-39]. In summary, BLNK has a dual function in B cell 
development by promoting differentiation and down regulating proliferation.  
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   Another signaling molecule with a potential role in B cell development is Btk. Studies have 
illustrated that Btk has an important role in the progression of pre-B cells to immature B 
cells. Also, Btk has a role in limiting pre-B cell proliferation, as Btk deficient pre-B cells 
exhibit increased proliferative response to IL-7 [40, 41].  
  In summary, B cell development is carried out through a balanced and tightly regulated 
interaction between proliferation and differentiation signaling pathways. Disruptions at any 
level (transcriptional, cytokine-cytokine receptor signaling, pre-BCR signaling) in B cell 
development can lead to B cell arrest and leukemia. Dysregulation of the proteins mentioned 
above by mutations, deletions, and repression has been reported in B cell acute lymphoblastic 
patients.  
1.2 B cell acute lymphoblastic leukemia (B-ALL):    
B cell acute lymphoblastic leukemia is a clonal malignant disease characterized by a block of 
B cell differentiation and the accumulation of these early B cells [42]. B-ALL represents 80 
% of the cases of childhood leukemia, and can be further divided into subgroups according to 
the associated genetic lesions [43]. These genetic lesions could be due to aneuploidy that is 
found in hyperdiploidy and hypodiploidy B-ALL subtypes. Also, genetic lesions could be 
due to chromosomal translocations that can lead to either deregulated expression of proto-
oncogenes or the expression of a fusion genes with properties different from their wild-type 
counterparts [44]. Examples of chromosomal translocations in B-ALL subtypes include 
ETV6-RUNX1, BCR-ABL1, TCF3-PBX1, and many others. There is an accumulation of 
evidence that many of these chromosomal translocations occur prenatally, suggesting that 
these chromosomal translocations push the cells toward a pre-leukemic state. Cooperating 
mutations are required for the cells to become fully transformed [1, 45]. Recent studies of 
genome wide profiling of B-ALL have increased our understanding of the biology and the 
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molecular pathways affected in each subtype of B-ALL, and of the cooperating mutations 
occur in B-ALL [46-48]. First, microarray gene expression profiling of B-ALL has illustrated 
that known genetic lesion subtypes of B-ALL have distinct gene expression profiles that are 
different from one another. In addition, these studies led to the discovery of a novel group of 
ALL without known chromosomal translocations [48].  Second, studies with SNP arrays 
have identified novel altered genes in B-ALL. The two most important findings from the 
SNP array studies are: 1) in over two thirds of B-ALL cases, genes encoding transcriptional 
regulators involved in the regulation of B cell development were mutated one example is 
PU.1 [47, 49]; 2) the nature and the number of genetic lesions are different among B-ALL 
subtypes. For example, in ETV6-RUNX1 and BCR-ABL1 it has been reported that 6-8 
genetic lesions are found per case. On the other hand, ALL cases with MLL rearrangements 
had much fewer numbers of genetic lesions [50].  
  In conclusion, each B-ALL subtype has a unique gene expression profile, which suggests 
that underlying biology and the affected pathways in each subtype are different among the 
subgroups. In addition, most of the genes affected by deletion, translocations and sequence 
mutations are genes encoding transcriptional regulators of B cell development. This may 
explain the block of B cell differentiation in B-ALL.  
1.3 Purine-Rich Box1 (PU.1):  
The transcription factor PU.1 belongs to the E26 transformation-specific (ETS) family. PU.1 
was discovered in murine erythroleukemia, which was caused by the proviral integration of 
the spleen focus-forming virus SFFV [51]. PU.1 is encoded by the SFFV proviral integration 
site 1 (Sfpi1) in mice and SPI1 in humans [52]. It has three functional domains: the DNA 
binding domain (ETS domain), a PEST domain, and a transactivation domain. The ETS 
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domain recognizes the consensus core sequence “ PU-box” GGAA or AGAA [53]. Studies of 
PU.1 have shown the critical role that PU.1 has in regulating the differentiation of different 
hematopoietic cells.  
1.3.1 The Expression and Regulation of PU.1 in B Cell development:  
PU.1 is expressed only in the hematopoietic system. PU.1 expression levels are a critical 
factor in determining the fate of differentiated hematopoietic cells. Studies have showen that 
PU.1 is expressed at low levels in early hematopoietic progenitor cells including CMP and 
CLP [54, 55]. It has been shown that PU.1 expression levels increase during myeloid 
differentiation, and decrease during B cell differentiation [54, 55]. Fine-tuning and tight 
regulation of PU.1 concentration is crucial for the development and function of B cells. 
Studies have shown that PU.1 concentration in macrophages is ~5 fold higher compared to B 
cells, and this is essential for the normal development of both cell types [56, 57].  
1.3.2 The Role of PU.1 in B cell development and its target genes:  
The importance of PU.1 in early B cell development has been demonstrated through gene 
knock out studies. Mice with homozygous null mutations of PU.1 have no B, T, or myeloid 
progenitor cells [58]. In addition, multipotential lymphoid-myeloid progenitors from the fetal 
liver of Sfpi1-/-  mice failed to differentiate into pro-B cells in response to stromal cell contact 
and IL7 [59]. These findings were explained by the impaired expression of the IL-7R in fetal 
liver cells. Therefore, PU.1 regulates early B cell development by the regulation of IL-7R 
[21]. However, PU.1 does not have a major role in B cell development after the commitment 
to B cell lineage. This was shown by the conditional deletion of PU.1 in B cells, which had 
minimal functional defects and resulted in normal B cell development [60], suggesting that 
the function of PU.1 in B cells could be complemented by the related transcription factor 
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SPIB. 
1.4 Spleen Virus Integration Site (Spi-B):  
The transcription factor Spi-B also belongs to the ETS family. PU.1 and Spi-B share 67% 
homology. In addition, Spi-B binds to the same consensus core sequence “ PU-box”. This 
suggests that Spi-B could regulate PU.1 target genes [61, 62]. 
1.4.1 The Expression and the Role of Spi-B in B Cell Development:  
Spi-B expression in B cells starts at the pro-B stage of B cell development. Spi-B has an 
overlapping pattern of expression with PU.1 in B cells, and binds to the same consensus core 
sequence. This suggests that PU.1 and Spi-B are functionally redundant in B cells [62]. In 
contrast to Sfpi1-/- mice, Spi-B-/- mice have normal hematopoietic development of all cell 
lineages. However, Spi-B-/- B cells have functional defects in the response to antigenic 
stimulation through the BCR and the amount of antibody produced after immunization. In 
addition, these B cells proliferate poorly in vitro in response to BCR stimulation and in 
response to  lipopolysaccharide (LPS) stimulation [63]. These results suggested that Spib-/- B 
cells are defective in one or more BCR signaling components, which could be directly 
regulated by Spi-B. In addition, Sfpi1+/- Spi-B-/- B cells exhibit more extensive defects in BCR 
signaling [64]. Therefore, PU.1 and Spi-B have an important role in regulating BCR 
signaling.  
1.5 The role of PU.1 and Spi-B in B-ALL:   
Our lab has provided direct evidence that PU.1 and Spi-B act as complementary tumor 
suppressor genes in B cells. This was done by generating conditional PU.1 knockout mice on 
a Spib-/- background. These mice developed B cell acute lymphoblastic leukemia with 100% 
incidence [65]. In addition, a recent study with transgenic mice expressing the human ETV6-
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RUNX1 revealed that SPIB transcript levels were reduced [66]. Another study with two 
human leukemia cell lines, AT-2 and REH, which express ETV6-RUNX1, suggested that 
SPIB was one of the top genes that were most up regulated after knocking down the ETV6-
RUNX1 fusion protein [67]. PU.1 mutations have been reported in relapsed B-ALL patients 
[49]. In conclusion, these studies clearly show that loss of PU.1 and SPIB could play a role in 
the leukemogenesis of B-ALL.  
1.6 ETV6-RUNX1 acute lymphoblastic leukemia:  
The chromosomal translocation t(12;21) fuses the ETV6 (TEL) gene to the RUNX1 (AML1) 
gene. This is the most common chromosomal alteration in pediatric B cell acute 
lymphoblastic leukemia, representing 25% of the cases [68]. ETV6-RUNX1 fusions can arise 
prenatally as an initiating event, which can contribute to the persistence of pre-leukemic 
clones. However, these persistent pre-leukemic clone cells cannot become fully transformed 
unless additional genetic mutations are acquired. The molecular mechanism underlying 
ETV6-RUNX1 function is to interfere with normal RUNX1 function. ETV6-RUNX1 
represses RUNX1 target genes by the recruitment of nuclear core repressor/histone 
deacetylase complexes [69]. RUNX1 is a transcription factor that has crucial regulatory 
function in the development of multiple blood cells. Conditional knock out of RUNX1 in the 
bone marrow has revealed that RUNX1 is required for the terminal differentiation of B cells 
[70]. RUNX1 regulates and physically interacts with key transcription factors in B cell 
development such as PU.1 and PAX5 [71, 72]. In addition to dysregulation of RUNX1 target 
genes, ETV6-RUNX1 is proposed to repress the expression of tumor suppressor genes and to 
increase the expression of anti-apoptotic genes [73]. In summary, ETV6-RUNX1 fusion 
protein plays a key role in transcriptional deregulation that might make the cells more 
persistent and susceptible to secondary mutations.  
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1.7 Hypothesis and objectives:  
The chromosomal translocation t(12;21) results in the fusion of the ETV6 (TEL) gene to the 
RUNX1 (AML1) gene. This is the most common chromosomal alteration in pediatric B cell 
acute lymphoblastic leukemia, representing 25% of the cases. ETV6-RUNX1 represses 
RUNX1 target genes by the recruitment of nuclear core repressor/histone deacetylase 
complexes. However, little is known about the target genes of ETV6-RUNX1 that are 
involved in promoting leukemogenesis. A recent study with transgenic mice carrying the 
human ETV6-RUNX1 revealed reduced SPIB transcript levels. Another study with two 
human leukemia cell lines AT-2 and REH, which express ETV6-RUNX1, suggested that 
SPIB was one of the top genes that were up regulated after knocking down the ETV6-
RUNX1 fusion protein. These studies lead to our hypothesis that ETV6-RUNX1 functions 
as an oncogenic driver by repressing SPIB transcription, leading to impaired B cell 
receptor signaling.  
To test this hypothesis, the following aims were conducted:  
1. To determine what target genes and pathways are affected by the loss of PU.1 and 
Spi-B in B  cell acute lymphoblastic leukemia (Chapter 3). 
2. To determine the expression levels of the SPIB gene before and after knocking down 
ETV6-RUNX1, and the molecular mechanism of how SPIB is regulated by ETV6-
RUNX1 (Chapter 4). 
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CHAPTER 2: Materials and Methods 
 
2.1 Mouse strains:  
Mice used in this study were Spib -/ - (ΔB mice) and CD19+cre Sfpi1lox/lox Spib-/- (ΔBP 
LEUK mice). Mice mating and breeding was done in concordance with an approved animal 
care protocol by the University of Western Ontario Council on animal care. All mice were on 
the C57BL/6 background. CD19cre/cre  mice were mated to Sfpi1lox/lox  mice to generate 
CD19+cre Sfpi1+/lox mice. Then, these mice were mated to Spib-/- mice to generate CD19+cre 
Sfpi1+/lox Spib+/- mice. Lastly, these mice were intercrossed to generate CD19+cre Sfpi1lox/lox 
Spib-/- (ΔBP LEUK mice) [65].  
2.2 Cell sorting:     
Single cell suspensions from the spleen of mice were stained with phycoerythrin (PE)–
conjugated anti-CD19 (1D3), and allophycocyanin-conjugated anti-B220 (RA3-6B2) (BD 
Pharmingen, Franklin Lakes, NJ, USA). Sorting of antibody-stained cells was done using the 
FACSAria II system.  
2.3 Affymetrix Mouse Exon Array hybridization:  
2.3.1 RNA isolation and evaluation:  
RNA extraction was done using RNA Bee RNA Isolation Agent (Tel-Test Friendswood, 
Texas). RNA concentration and purity were measured by the Nanodrop ND-1000 
Spectrophotometer	  Thermo Fisher Scientific Inc.  All RNA samples had high purity, with a 
260/280 ratio of 1.8-2.1. RNA integrity was analyzed using Agilent 2100 Bioanalyzer Scans.  
The integrity of RNA was determined by two factors. First, the RNA integrity number (RIN), 
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which can vary from 0 (degraded RNA) to 10 (intact RNA). Second, the ratio of 28s/18s 
ribosomal RNA, which is 2.0 for intact RNA. All samples had a RIN of (8-9.3) and a ratio of 
28s/18s of (1.9-2.7).  
2.3.2 RNA processing: 
RNA processing for hybridization was done at the London Regional Genomic Center, 
according to the manufacture’s instruction (Affymetrix).  Probes for the exon arrays were 
designed in the anti-sense configuration. Therefore, RNA had to be treated to produce a 
labeled single stranded sequence in the sense orientation before hybridization. In brief, RNA 
was converted to cDNA, followed by in vitro transcription to amplify the cDNA and produce 
cRNA. Then, a second cycle of cDNA synthesis was applied using the cRNA to produce 
single strand DNA in the sense orientation. This DNA is enzymatically fragmented and 
fluorescently labeled, then hybridized on Affymetrix Mouse Exon 1.0 ST Arrays.  A total of 
eight arrays were hybridized at three different time points representing three batches of 
samples. Arrays were scanned using Affymetrix GeneChip Scanner 3000 7G, and converted 
to processed image. Then .CEL files were generated, containing the raw signal intensities 
(one signal intensity value per probe).  
2.4 Data pre-processing and batch effect removal:  
2.4.1 Data pre-processing:  
.CEL files were exported to Partek Genomic Suite software (Partek Inc., St. Louis, MO, 
USA), where all the steps of data pre-processing and data analysis were done.  Data pre-
processing for Affymetrix arrays included background correction, quintile normalization, 
log2 transformation, and summarization. All previous steps were done using the Robust 
Multiarray Analysis (RMA) technique, which is implanted in Partek software. First, 
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background correction for all exon arrays was done by predicting the hybridization properties 
of a given probe based on the GC-content, as probes with higher GC-content will hybridize 
better.  Second, a quintile normalization algorithm was applied to all exon arrays at the probe 
level, which makes the assumption that all arrays have an equal intensity distribution. Third, 
all signal intensity values for the arrays were transformed to log2 scale, and all subsequent 
analysis was done on these log-transformed values. Log transformation makes the intensity 
distribution symmetrical and bell shaped. Finally, summarization was done to convert 
multiple probe measurements into a single value of a probe sets.  Probe sets represent values 
at the exon level.  Additional summarization was applied on these probe sets values to 
convert them in to single value Meta-probe sets. These Meta-probe sets represent values at 
the gene level. All summarization steps were done using the median polish method.  After 
that, intensity values of probe sets for various controls were checked. All the arrays had their 
control values within the expected range.  Scan date was one of the major sources of 
variation that contributed to the variance between the samples. ComBat algorithm was used 
to remove the scan date factor of variation [74].  
2.4.2 Batch effect removal:  
In order to remove batch effect (scan date) between the batches, an Empirical Bayes method 
called Combating Batch Effects (ComBat) [74] was used. All work with removing the batch 
effect was done using the R script. In brief, R script was downloaded on the computer used in 
the London regional genomic center. Then a working directory was created. In the working 
directory, the ComBat.R script file, which has the ComBat code, was saved. Then, the gene 
expression file and the information file were created and saved in the working directory. 
After that, script codes were typed to run ComBat in R. codes that can be found in 
(http://www.bu.edu/jlab/wp-assets/ComBat/Usage.html). An output excel file with adjusted 
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data was generated. Finally, the adjusted data were copied and pasted in a new spreadsheet in 
Partek for data analysis [74].   
2.5 Data analysis: 
2.5.1 Differentially expressed genes:  
To identify differentially expressed genes between the three different populations, a one-way 
analysis of variance (ANOVA) was used. Then two lists were created from the ANOVA 
spreadsheet. First, genes increased in ΔBP LEUK cells compared to ΔB cells with > 1.5 fold 
change and with p <0.05 was generated. Second, genes decreased in ΔBP LEUK cells 
compared to ΔB cells with > - 1.5 fold change and with p < 0.05 was generated.  
2.5.2 Partek pathway:  
The increased and decreased lists of genes were assessed for over representation analysis 
using Fisher exact test to identify significantly enriched biological pathways. These 
biological pathways were generated using the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database.  
2.5.3 Heat map generation:  
Heat maps were generated using Hierarchical Clustering Explorer. Log2 transformed values 
were used for the top 100 genes that were up/down regulated in ΔBP LEUK cells compared 
to ΔB cells.  
2.6 Real-Time quantitative PCR (qPCR):  
  RNA extraction was done using RNA Bee RNA Isolation Agent (Tel-Test Friendswood, 
Texas). RNA was reverse transcribed into cDNA using the iScript DNA synthesis kit (Bio-
Rad, Hercules, CA). qPCR was done using the iQ SYBR Green Supermix Kit (Bio-Rad). A 
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Rotor-Gene 6000 instrument was used to run the qPCR reactions. Beta-2 microglobulin 
(B2m) was chosen as a reference gene to normalize the data to correct for differences in 
quantities of cDNA used as template. B2m had consistent CT values between samples, which 
made it an optimal reference gene. Relative expression software tool (REST), which put in to 
consideration the differences in the efficiency between the primers, was used to measure the 
relative expression levels between the samples [75]. Each result was performed in triplicate 
and significance was determined using the Students t-test. 
  Efficiency for each primer was calculated using two fold serial dilution standard curves. 
Also, primer specificity was tested by gel electrophoresis. Primer sequences and efficiency 
are listed in Table 2.1. 
2.7 Bioinformatics analysis:  
2.7.1 Matinspector: 
Matinspector [76] was used to identify predicted RUNX1 binding sites on the SPIB and 
POLD1 locus. 0.8 was the matrix score cutoff for predicted RUNX1binding sites to be 
chosen for further analysis.  
2.7.2 Macvector:  
Multiple alignments of the intron one of the SPIB for five mammalian species (rat, mouse, 
human, cow, dog) were done using the CLUSTALW method in Macvector (Accelrys, San 
Diego, CA). Sequences were acquired from the Ensemble.org database.  
2.7.3 UCSC Genome Browser website:  
UCSC Genome Browser website was used to visualize the ENCODE data (DNase I 
hypersensitivity sites and histone acetylation marker (H3K27AC)), and to cross reference the 
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predicted RUNX1 binding sites to transcriptionally active sites in B cell line GM12878 [77].   
2.8 Cell culture:  
 The REH (B –ALL) cell line was purchased from the American Type Culture Collection 
(ATCC), Manassas, USA). These cells were cultured in complete medium containing 
Roswell Park Memorial Institute (RPMI), 10% fetal bovine serum, 100 U/mL 
penicillin/streptomycin, 2mM L-glutamine, and 5 Χ 10-5 M 2-mercaptoethanol. Cell cultures 
were maintained at 37 0C in 5% CO2. atmosphere.  
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Table 2.1 qPCR primer sequences and efficiencies:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENE 
(mouse) 
Primer sequence  Efficiency 
B2M F 5' TGGCTCACACTGAATTCACCCCCA'3 0.97 
B2M R 5' TCTCGATCCCAGTAGACGGTCTTGG'3 
Tcf7l2 F 5'CCGCCCGAACCCTCCATTTTCA'3 0.98 
Tcf7l2 R 5'TGCTCTGGAGGCTTCCTGCTTG'3 
Lgr5 F 5' TCAAGTTCAAGATGAGCGGGACCT 3' 0.98 
Lgr5 R 5' AGCCAGCTACCAAATAGGTGCTCA 3' 
lef1 F 5' TGGCATCCCTCATCCAGCTATTGT 3' 1 
lef1 R 5' TGAGGCTTCACGTGCATTAGGTCA 3'  
Blnk F 5'TCCAAGTCATCTTTGCCTGCC3' 1.05 
Blnk R 5'TGCATTCGGTAGGGGAGGAAC3' 
Btk F 5'ACAGATTCCGAGGAGAGGTGAGG3' 1.05 
Btk R 5'GGTCCTTCATCATATACAACCTGGAATGG3' 
Enpep F 5'ACCAGGTCGTGTGAGCAGG3' 0.9 
Enpep R 5'CAGACATTCTGGTCCTGAGGAGG3' 
Il7ra F 5'AGCAAGGGGTGAAAGCAACTGG3' 1.05 
Il7ra R 5'TCGGACTTTGATTTCATACATTGCTTTTGG3
' 
Ptprc F 5'AGAAACGCCTAAGCCTAGTTGTGG3' 1.07 
Ptprc R 5'TGGGGTTTAGATGCAGACTCAGG3' 
Lyn F 5' CAGCAAAGGCCAGTTCCTGA 3' 0.93 
Lyn R 5' ACAAGTCATCTGGGTGGATGC 3' 
Vav 2 F 5' GCAAAGGGATCAGGCCATTTC 3' 0.95 
Vav 2 R  5' ATCTTCACACGGGACACAGTC 3' 
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2.9 Chromatin immunoprecipitation (ChIP):  
  
REH cells were cross-linked with formaldehyde for 10 minutes at room temperature.  Cross-
linked cells were neutralized with 125 mM glycine, and washed with cold phosphate buffered 
saline. Fixed cells were lysed with buffer containing protease inhibitors (50 mM Tris-HCl 
[pH 8.1], 10 mM EDTA, 1% SDS).  Samples were sonicated using a Biorupture (Diagenode, 
Denville, USA) to an average DNA length of 200-1000 bp.  Sonicated chromatin was 
incubated with rabbit anti-RUNX1, or control rabbit anti-IgG ( ChIP grade, Abcam), which 
were coupled with protein G DynaBeads overnight at 4 ̊C. These beads were collected and 
washed five times with different washing buffers. Beads were washed once with low-salt 
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, 150 mM NaCl). 
Then, beads were washed once with high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, 500 mM NaCl). After that, beads washed with LiCl buffer (0.25 M 
LiCl, 1% Nonidet P-40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-Cl). Finally, beads 
were washed twice with Tris-EDTA buffer at pH 8.  After washing, antibody, beads, 
chromatin complex were eluted with elution buffer (1% SDS, 0.1 M NaHCO3). Eluted 
solution was incubated at 65 oC overnight to reverse the cross-linking. Then, DNA was 
purified using the Qia-Quick PCR purification Kit (Qiagen). qPCR method was used to 
measure the enrichment of the immunoprecipitated DNA using specific primers designed to 
amplify the predicted RUNX1 binding sites (Table 2.2).  Fold enrichment and percent input 
were calculated.  
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Table 2.2 ChIP primer sequences:  
GENE  RUNX1 binding postion  primer sequence  
SPIB  P-2 intron1  F 5' CCACCTGCACTGCCCCTC 3' 
R 5' TGGACCCCTCCCCTCCAC 3'  
P-3 intron1 conserved  F 5' GAGTCCGGTGAATGTGGTGG 3' 
R 5' CTGGAGGGGGAGAGACACAG 3' 
P-4 intron 2  F  5' CGGAATACTATACCCAACACCCTTG 3'  
R  5' GCATAAACAGGGGCTTTCTTTCAA 3' 
P-5 3' down stream  F 5' AAAACAATTAGCCGAGCGTGG 3' 
R 5' ACAGCTCACTACAGCCTCCTA 3' 
POLD1 P-1 intron20  F 5' TGGTGAAGCAGTGGAAAGAGTC 3' 
R 5' AGACCAGGATGAGCTCTTAGGG 3' 
C4ORFII Negative control  F 5' GTATTCAGCCAGCCTTTTCTTGG 3' 
R 5' ACACAGCTTATCTCAAGGTGACA 3'  
SPIB NC intron5 8050 to 8198 F 5' AGGCATGATGGTGCATACTTGT 3' 
R 5' TTTTTCAAGGCAGGGTCTCGTT 3'  
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CHAPTER 3:  Gene Expression Analysis of B cell Acute Lymphoblastic Leukemia 
Caused by the Deletion of Genes Encoding PU.1 and Spi-B. 
3.1 Introduction: 
Our lab generated conditional PU.1 knockout mice on a Spib-/- background, where the 
Sfpi1lox allele is excised under the control of the B cell specific CD19 locus (CD19+/cre 
Sfpi1lox/lox Spib-/- mice) henceforth called ΔBP LEUK mice. These mice developed B cell 
acute lymphoblastic leukemia (ALL) with 100% incidence. Characterization of these B-ALL 
cells revealed that 100% express BP-1 and CD93, which are markers of immature B cells. 
These results suggested that PU.1 and Spi-B are important in normal B cell differentiation 
[65].  To understand how the loss of PU.1 and Spi-B led to B-ALL, microarray gene 
expression profiling was used.  
   Microarray technology has the advantage of measuring the transcript levels of thousands of 
genes in one assay. It helps the scientist to determine which genes are associated with certain 
diseases and/or treatment, by comparing diseased/treated and control expression profiles 
[74].  In this study, Affymetrix mouse Exon Arrays were used to gain extensive insight of 
target genes and pathways affected by the loss of PU.1 and Spi-B in B-ALL cells compared 
to the control cells.   
3.2 Sorting of B cell populations for gene expression analysis:  
   Two cell surface markers CD19 and B220 were selected to isolate the different B cell 
populations. CD19 is a known B cell specific marker, which is expressed once the 
lymphocyte progenitor is committed to B cell specification. It continues to be expressed on 
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mature B cells [78]. The second marker B220 is a known PU.1 target gene [79]. Absence of 
PU.1 expression will block the expression of B220, which serves as a good indicator to 
identify the leukemic cells knocked out for PU.1.  
  The three B cell populations were sorted including the control B cells, B-ALL cells, and B 
cells from ΔBP LEUK mice. Control B cells were sorted from spleens of mice lacking Spi-B 
in the germ line (CD19+/+Sfpi1lox/loxSpib-/-) henceforth called ΔB mice. Flow cytometric 
analysis determined that 56% of the ΔB splenocytes were CD19+B220+ (Figure 3.1 left 
panel). Second, B-ALL cells were sorted from the spleens of ΔBP LEUK mice. These B-
ALL cells were CD19+B220-  (ΔBP LEUK cells), and represented 41% of the whole spleen 
cells (Figure 3.1 right panel). Lastly, we sorted an interesting small population of 
CD19+B220+ (ΔBP cells) from the spleens of ΔBP LEUK mice, which consisted of 8% of 
the total splenocytes (Figure 3.1 left panel). Eight samples were used (ΔB cells   n = three, 
ΔBP LEUK cells n = 3 ΔBP cells n = 2). These replicates were processed in three time 
points, representing three batches/groups of samples (Table 3.1). RNA was extracted from 
these cells using RNA Bee RNA Isolation Agent and processed according to the 
manufactures guidelines (Affymetrix, Inc., Santa Clara, CA). The processed RNA was 
hybridized to the Affymetrix mouse Exon Arrays. Then, arrays were scanned using 
Affymetrix® Scanner 3000 7G (Figure 3.2).  
         The raw signal intensities generated from the microarray experiments need to be 
preprocessed before analysis. The purpose of the preprocessing step is to remove most of the 
technical sources of variation [80]. These systemic variations arise due to  
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Figure 3.1 Identification of control and leukemic B cell population  
Three B cell populations were sorted based on the expression of CD19 and B220 surface 
markers. A representative flow cytometric panel is shown. The left panel represents sorted 
CD19+B220+  splenocytes from the control mice (ΔB). The right panel represents sorted 
splenocytes from leukemic mice (ΔBP). CD19+B220- (ΔBP LEUK) and CD19+B220+ (ΔBP 
cells) were sorted from ΔBP mice.  
 
 
 
 
 
 
ΔB	   ΔBP	  LEUK	   ΔBP	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 Table 3.1 The number of replicates for each cell population and time processed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Time point     Population  Mouse number         Genotype 
  January  
   2011 
 ΔB cells        667 Spib -/ - 
ΔBP cells 
 
       669 CD19+cre Sfpi1lox/lox Spib-/- 
ΔBP LEUK cells 
 
       668 
   June  
   2011 
ΔBP cells        760 
 ΔB cells        761 Spib -/ - 
 ΔB cells        762 
   July  
   2011 
ΔBP LEUK cells        782 CD19+cre Sfpi1lox/lox Spib-/- 
ΔBP LEUK cells        783 
25	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Overview of work flow for Affymetrix  Mouse Exon 1.0 ST Arrays   
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experiments being performed at different times, on different chip lots, with different 
technicians, or even with changing atmospheric ozone levels. Careful assessment and 
removal of systemic variations is important for reducing bias, which can be strong enough to 
mask true biological differences [81].  The first step taken to remove technical variation is 
background correction (e.g. caused by incomplete washing). Second step is normalization, 
which makes samples comparable to each other by homogenization of the signal intensity 
distribution (Figure 3.2) [80]. However, these normalization methods are not designed to 
remove systemic variations between two or more different batch/ group of samples. As we 
had three batches of samples, an additional approach was needed for removing systemic 
variations between batches/groups [81].   
3.2 Improved correlations between the replicates within each population after batch 
effect removal 
    The term ‘batch’ refers to microarray experiments processed simultaneously at one site 
and using the same platform (microarray chip). The term ‘batch effect’ will be used to 
describe systematic differences between the measurements of different batches [81].  
  To assess and adjust our data for batch effect, an Empirical Bayes Method called ComBat 
was used. This method is very robust in removing batch effect in small size batches, as 
compared to other methods that require at least twenty-five samples in each batch [74]. 
Principal Component Analysis (PCA) was used to evaluate the correlation between the 
replicates within each population before and after adjusting the data sets for batch effect. 
Results of PCA analysis are visualized in a three-dimensional plot. Eight dots were observed,  
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with each dot representing the gene expression of one sample. Before the removal of batch 
effect, replicates of each cell population were scattered (not clustered) indicating different 
gene expression profiles within the same population (Figure 3.3A). These differences in the 
gene expression profile within the same population were due to the batch effect, which 
confounded the signal values of the expression profiles. After the removal of batch effect, the 
replicates of each cell population were grouped together indicating similar gene expression 
profiles (Figure 3.3B). These results revealed the degree of  batch effect within our dataset, 
and suggested that ComBat was an effective tool for removing batch effect. 
3.3 Removing batch effect from the data set increases the number of significantly 
differentially expressed genes 
  To determine changes in gene expression, a one-way ANOVA test was used to generate 
two lists; increased and decreased in ΔBP LEUK cells compared to ΔB cells. After filtering 
genes with more than 1.5 fold change and P ≥ 0.05, there were 2908 genes down-regulated in 
ΔBP LEUK cells after removal of batch effect compared to only 1161 genes prior (Figure 
3.4A). Also, there were 3477 genes up-regulated in ΔBP LEUK cells after removal of batch 
effect compared to only 1636 genes prior (Figure 3.4B). This data illustrates that after 
removing batch effect from our data set, the total number of significantly altered genes were 
increased by almost double.  
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Figure 3.3 Improved correlation between replicates for each population after removing 
the batch effect  
 A. Before batch effect removal. ΔBP LEUK cell population (red dots) were far from each 
other, and ΔB cell population (green dots) are widely separated indicating variation in gene 
expression between the replicates of each population. B. After batch effect removal. 
Removing batch effect grouped ΔBP LEUK cell populations (red dots), and ΔB cell 
populations (green dots) together indicating similar gene expression within each population 
as expected.   
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Figure 3.4 Removing the batch effect from the dataset increases the number of 
significantly differentially expressed genes 
A Venn diagram was used to illustrate the total number of significantly differentially 
expressed genes before (green) and after (light red) the batch effect removal in two lists. A. 
List of genes with decreased expression in ΔBP LEUK cells compared to ΔB cells. It 
was observed that after batch effect removal, the total number of significantly altered genes 
is 2908 compared to 1161 genes before batch effect removal. B. List of genes with 
increased expression in ΔBP LEUK cells compared to ΔB cells. It was observed that after 
batch effect removal, the total number of significantly altered genes is 3477 compared to 
1636 genes before batch effect removal.  
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3.4 High fold changes in differentially expressed genes in ΔBP LEUK cells compared to 
ΔB cells  
  The median of the top 100 genes that were decreased in expression in ΔBP LEUK cells 
compared to ΔB cells was -56 fold (Table 3.2 only showing the top 30 genes). The median of 
the top 100 genes that were increased in expression in ΔBP LEUK cells compared to ΔB 
cells was 27 fold (Table 3.3 only showing the top 30 genes). These are large changes and 
may reflect the fact that PU.1 is a key transcription factor in B cell development.  Heat maps 
were generated from the top 100 genes increased and decreased in expression in ΔBP LEUK 
cells compared to ΔB cells using the signal intensity value for each replicate. Red and blue 
colors represent an increase and a decrease in the signal intensity respectively. In the heat 
map of the top 100 genes decreased in ΔBP LEUK, the ΔBP LEUK population columns 
were colored blue compared to ΔB and ΔBP populations which were colored red (Figure 
3.5A). In the heat map of the top 100 genes increased in ΔBP LEUK cells compared to ΔB 
cells, an interesting trend was observed. From the right to the left, there was a gradual 
increase in the intensity from ΔB cell population (blue color) to ΔBP LEUK (red color) cell 
population, which suggested that ΔBP cell population was at an intermediate stage between 
the two (Figure 3.5B).  
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Table 3.2 The top 30 genes with decreased expression in ΔBP LEUK cells compared to 
ΔB cells  
Transcript ID gene_assignment Gene 
Symbol 
p-
value 
Fold-
Change 
6868091 NM_029499 // Ms4a4c // membrane-
spanning 4-domains, subfamily A, 
member 4C // 19 
Ms4a4c 8.02E-
08 
-313.707 
6932118 NM_019992 // Stap1 // signal 
transducing adaptor family member 1 // 
5 E1|5 // 56 
Stap1 8.09E-
05 
-201.617 
6806245 NM_010745 // Ly86 // lymphocyte 
antigen 86 // 13 A3.3|13 // 17084 /// 
NM_198610  
Ly86 2.18E-
07 
-190.898 
6850017 NM_010388 // H2-DMb2 // 
histocompatibility 2, class II, locus Mb2 
// 17 B1|17 18 
H2-
DMb2 
1.18E-
05 
-167.254 
6798285 NM_178911 // Pld4 // phospholipase D 
family, member 4 // 12 F1|12 // 104759 
///  
Pld4 1.79E-
06 
-160.007 
6827944 NM_183031 // Gpr183 // G protein-
coupled receptor 183 // 14 E5|14 // 
321019 ///  
Gpr183 8.06E-
09 
-155.01 
6938678 NM_030682 // Tlr1 // toll-like receptor 1 
// 5 C3.1|5 37.0 cM // 21897 /// ENSMU 
Tlr1 1.35E-
11 
-153.518 
6855018 NM_010378 // H2-Aa // 
histocompatibility 2, class II antigen A, 
alpha // 17 B1|1 
H2-Aa 4.28E-
07 
-153.485 
6765460 NM_007758 // Cr2 // complement 
receptor 2 // 1 H6|1 106.6 cM // 12902 /// 
ENSMUS 
Cr2 4.61E-
10 
-152.625 
6930383 NM_007646 // Cd38 // CD38 antigen // 5 
B3|5 28.0 cM // 12494 /// 
ENSMUST00000030 
Cd38 1.02E-
05 
-152.562 
6890068 NM_011246 // Rasgrp1 // RAS guanyl 
releasing protein 1 // 2 E5|2 65.0 cM // 
1941 
Rasgrp1 8.99E-
08 
-145.315 
6980089 NM_013517 // Fcer2a // Fc receptor, 
IgE, low affinity II, alpha polypeptide // 
8 
Fcer2a 1.28E-
11 
-143.523 
6848579 NM_009835 // Ccr6 // chemokine (C-C 
motif) receptor 6 // 17 A1|17 // 12458 /// 
N 
Ccr6 6.93E-
11 
-139.087 
6850012 NM_010386 // H2-DMa // 
histocompatibility 2, class II, locus DMa 
// 17 B1|17 18. 
H2-
DMa 
3.02E-
06 
-133.578 
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6755378 NM_133809 // Kmo // kynurenine 3-
monooxygenase (kynurenine 3-
hydroxylase) // 1 H 
Kmo 8.37E-
11 
-127.329 
6871542 NM_007641 // Ms4a1 // membrane-
spanning 4-domains, subfamily A, 
member 1 // 19 B 
Ms4a1 1.01E-
06 
-122.824 
6755282 NM_001013779 // Aim2 // absent in 
melanoma 2 // 1 H3|1 // 383619 /// 
ENSMUST0000 
Aim2 2.01E-
05 
-119.605 
6786249 NM_019549 // Plek // pleckstrin // 11 
A2|11 6.5 cM // 56193 /// 
ENSMUST000001028 
Plek 6.85E-
07 
-114.815 
6762603 NM_001111316 // Ptprc // protein 
tyrosine phosphatase, receptor type, C // 
1 E4| 
Ptprc 5.13E-
07 
-108.988 
6941645 NM_008052 // Dtx1 // deltex 1 homolog 
(Drosophila) // 5 F|5 65.0 cM // 14357 /// 
Dtx1 8.65E-
09 
-104.755 
6931217 NM_008453 // Klf3 // Kruppel-like 
factor 3 (basic) // 5 C3.1|5 // 16599 /// 
DQ98 
Klf3 8.33E-
08 
-101.631 
6964163 NM_021887 // Il21r // interleukin 21 
receptor // 7|7 F4 // 60504 /// 
ENSMUST0000 
Il21r 1.35E-
08 
-100.111 
7015521 NM_007807 // Cybb // cytochrome b-
245, beta polypeptide // X A1.1|X // 
13058 /// 
Cybb 6.82E-
05 
-94.7675 
6749392 NM_011487 // Stat4 // signal transducer 
and activator of transcription 4 // 1 C1 
Stat4 2.59E-
08 
-94.7443 
6818958 NM_030098 // Rnase6 // ribonuclease, 
RNase A family, 6 // 14 C1|14 // 78416 
///  
Rnase6 8.58E-
06 
-93.5864 
6848553 NM_145968 // Tagap // T-cell activation 
Rho GTPase-activating protein // 17 
A1|1 
Tagap 2.50E-
08 
-93.0906 
6827943 NM_182806 // Gpr18 // G protein-
coupled receptor 18 // 14 E5|14 68.0 cM 
// 11016 
Gpr18 3.47E-
09 
-89.0148 
6946028 NM_174990 // Gimap4 // GTPase, 
IMAP family member 4 // 6 B2.3|6 // 
107526 /// NM 
Gimap4 1.69E-
06 
-86.3424 
6839340 NM_007575 // Ciita // class II 
transactivator // 16 A1|16 // 12265 /// 
ENSMUST00 
Ciita 2.77E-
06 
-82.8095 
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Table 3.3 The top 30 genes with increased  expression in ΔBP LEUK cells compared to ΔB cells 
Transcript 
ID 
gene_assignment Gene 
Symbol 
p-value Fold-
Change 
6909278 NM_007934 // Enpep // glutamyl 
aminopeptidase // 3 G3|3 65.2 cM // 
13809 /// ENS 
Enpep 0.000531666 149.683 
6776185 NM_007706 // Socs2 // suppressor of 
cytokine signaling 2 // 10 C2|10 52.0 cM 
//  
Socs2 6.43E-05 145.08 
6905321 NM_019410 // Pfn2 // profilin 2 // 3 D|3 
29.3 cM // 18645 /// 
ENSMUST00000066882 
Pfn2 2.30E-05 74.9968 
6812386 NM_028784 // F13a1 // coagulation 
factor XIII, A1 subunit // 13 A3.3|13 // 
74145 
F13a1 5.32E-06 62.5917 
6970840 NM_172476 // Tmc7 // transmembrane 
channel-like gene family 7 // 7 F2|7 // 
20976 
Tmc7 1.00E-05 59.7736 
6874057 NM_010279 // Gfra1 // glial cell line 
derived neurotrophic factor family 
recepto 
Gfra1 6.16E-05 57.3056 
6883110 NM_001012704 // Wfdc13 // WAP four-
disulfide core domain 13 // 2H3|2 // 
408190 / 
Wfdc13 0.000842222 46.8146 
6777190 NM_010195 // Lgr5 // leucine rich repeat 
containing G protein coupled receptor 5 
Lgr5 0.000190008 46.3768 
6905746 NM_016753 // Lxn // latexin // 3 E1|3 
31.6 cM // 17035 /// 
ENSMUST00000058981 // 
Lxn 7.57E-05 45.9732 
6938217 NM_172710 // Sel1l3 // sel-1 suppressor 
of lin-12-like 3 (C. elegans) // 5 C1|5  
Sel1l3 1.43E-05 44.3316 
7014110 NM_023270 // Rnf128 // ring finger 
protein 128 // X F1|X // 66889 /// 
ENSMUST000 
Rnf128 0.000142421 42.1642 
6768014 NM_010288 // Gja1 // gap junction 
protein, alpha 1 // 10 B4|10 29.0 cM // 
14609  
Gja1 7.95E-06 41.822 
6901316 NM_130450 // Elovl6 // ELOVL family 
member 6, elongation of long chain fatty 
aci 
Elovl6 1.77E-05 41.5706 
6963854 NM_028930 // Tmc5 // transmembrane 
channel-like gene family 5 // 7|7 F3 // 
74424 
Tmc5 1.48E-05 41.2887 
6815259 NM_198408 // Crhbp // corticotropin 
releasing hormone binding protein // 13 
Crhbp 0.000134405 41.2017 
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D1|1 
6888340 NM_145526 // P2rx3 // purinergic 
receptor P2X, ligand-gated ion channel, 
3 // 2  
P2rx3 1.60E-07 41.0273 
6978354 NM_018882 // Gpr56 // G protein-
coupled receptor 56 // 8 D1|8 45.0 cM // 
14766 / 
Gpr56 7.95E-06 40.7432 
6921929 NM_019427 // Epb4.1l4b // erythrocyte 
protein band 4.1-like 4b // 4 B3|4 26.0 
cM 
Epb4.1l4b 1.10E-05 40.0716 
6904066 NM_013531 // Gnb4 // guanine 
nucleotide binding protein (G protein), 
beta 4 // 3 
Gnb4 0.000122039 37.7548 
6820113 NM_008115 // Gfra2 // glial cell line 
derived neurotrophic factor family 
recepto 
Gfra2 0.00118214 37.2954 
6824743 NM_010590 // Jub // ajuba // 14 C3|14 // 
16475 /// ENSMUST00000054487 // Jub 
//  
Jub 1.68E-06 34.2544 
6855659 NM_001025250 // Vegfa // vascular 
endothelial growth factor A // 17 C|17 
24.2 cM 
Vegfa 0.000456204 34.242 
6922026 NM_025968 // Ptgr1 // prostaglandin 
reductase 1 // 4|4 C1 // 67103 /// 
ENSMUST00 
Ptgr1 3.71E-05 33.268 
6784062 NM_010517 // Igfbp4 // insulin-like 
growth factor binding protein 4 // 11 
D|11 / 
Igfbp4 1.02E-06 32.1901 
6861173 NM_001001979 // Megf10 // multiple 
EGF-like-domains 10 // 18 D3|18 // 
70417 ///  
Megf10 0.000119756 31.747 
6912517 NM_027491 // Rragd // Ras-related GTP 
binding D // 4 A5|4 11.4 cM // 52187 /// 
E 
Rragd 5.78E-06 31.7333 
6839836 NM_033474 // Arvcf // armadillo repeat 
gene deleted in velo-cardio-facial syndro 
Arvcf 3.53E-09 31.6938 
6791229 NM_001163608 // Plxdc1 // plexin 
domain containing 1 // 11 D|11 // 72324 
/// NM_ 
Plxdc1 5.99E-07 31.2134 
6871471 NM_019699 // Fads2 // fatty acid 
desaturase 2 // 19|19 B // 56473 /// 
ENSMUST000 
Fads2 0.000455211 30.9533 
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Figure 3.5 Heat Maps of the top 100 genes differentially expressed in ΔBP LEUK cells 
compared to ΔB cells.  
Heat maps were generated using the signal intensity value (red color = increased, blue color 
= decreased) for each replicate. Each column represents one replicate. Replicates are aligned 
together for each cell population. A. Heat map of the top 100 genes decreased in ΔBP LEUK 
cells compared to ΔB cells. B. Heat map of the top 100 genes increased in ΔBP LEUK cells 
compared to ΔB cells. 
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3.5 44 genes known to be activated by PU.1 were reduced in our data set  
  There are at least 110 genes known to be activated by PU.1 published in the literature 
(Figure 3.6) [82]. From the 110 target genes 44 had decreased expression in ΔBP LEUK 
cells compared to ΔB cells (Figure 3.7A). 11 of the 110 target genes had increased 
expression in ΔBP LEUK cells compared to ΔB cells (Figure 3.7B). 55 of the 110 target 
genes did not meet the cutoff of 1.5 fold change or the significance of P ≤ 0.05. These results 
show that 40% of known PU.1 target genes were reduced in our data set.   
3.6 Signaling pathways predicted to be the most affected by decreased gene expression 
  To determine which pathways were affected due to the loss of PU.1 and Spi-B in ΔBP 
LEUK cells compared to ΔB cells, we used the Partek Pathway tool to map the genes in the 
increased and decreased lists on to biological pathways. An enrichment score with P values 
was generated for each pathway using Fisher exact test or chi-square test.  
   Most of the genes that were decreased in ΔBP LEUK cells compared to ΔB cells were 
mapped to signaling pathways (Table 3.4). The top category affected in the list was the B 
cell receptor-signaling pathway (Figure 3.8). As shown, most of the genes in this pathway 
were reduced (blue colored). This data suggests the importance of PU.1 and Spi-B 
transcription factors in B cell receptor signaling pathway, and correlated with an arrest in cell 
differentiation in ΔBP LEUK cells.       
3.7 Cell cycle regulation pathways predicted to be the most affected by increased gene 
expression 
  Most of the genes that were increased in expression in ΔBP LEUK cells compared to ΔB 
cells were mapped to cell cycle regulation, DNA replication, and mismatch repair pathways 
(Table 3.5). These results correlated with an increase in cell proliferation. 
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Figure 3.6 The identities of genes directly activated by PU.1 
Genes activated by the transcription factor PU.1 are indicated in alphabetical order using the 
human nomenclature. Genes are grouped according to the sub cellular location of the 
proteins that are the products of the indicated genes. Sub cellular location is indicated on the 
left side.  
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Figure 3.7 44 genes known to be activated by PU.1 were reduced in our data set 
 A. Intersect between the list of PU.1 known target genes (110) represented by 136 
probe sets (green) and the list of genes were decreased in expression in ΔBP LEUK cells 
compared to ΔB cells (pink). 44 genes known to be activated by PU.1 represented by 52 
probe sets were reduced in expression in ΔBP LEUK cells compared to ΔB. B. Intersect 
between the list of PU.1 known target genes (110) represented by 136 probe sets (green) 
and the list of genes were increased in expression in ΔBP LEUK cells compared to ΔB 
cells (pink). 11 genes known to be activated by PU.1 were increased in expression in in ΔBP 
LEUK cells compared to ΔB.  
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Table 3.4 The top 20 pathways generated from the gene list that were decreased in 
expression in ΔBP LEUK cells compared to ΔB cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway Name Enrichment Score Enrichment p-value 
B cell receptor signaling pathway 56.9403 1.87E-25 
Olfactory transduction 55.859 5.51E-25 
Osteoclast differentiation 41.7813 7.16E-19 
Antigen processing and presentation 34.4911 1.05E-15 
T cell receptor signaling pathway 32.5841 7.06E-15 
Leishmaniasis 29.2515 1.98E-13 
Influenza A 28.0184 6.79E-13 
Toll-like receptor signaling pathway 25.7857 6.33E-12 
Leukocyte transendothelial migration 24.2586 2.91E-11 
Viral myocarditis 23.889 4.22E-11 
NOD-like receptor signaling pathway 23.6298 5.47E-11 
Herpes simplex infection 22.3261 2.01E-10 
Legionellosis 22.0244 2.72E-10 
Tuberculosis 19.6472 2.93E-09 
Toxoplasmosis 18.2024 1.24E-08 
Allograft rejection 17.5291 2.44E-08 
Type I diabetes mellitus 16.7667 5.23E-08 
Intestinal immune network for IgA production 16.5588 6.44E-08 
Lysosome 16.2362 8.89E-08 
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Table 3.5 The top 20 pathways generated from the gene list that were increased in 
expression in ΔBP LEUK cells compared to ΔB cells 
 
 
 
 
 
 
 
 
 
 
Pathway Name Enrichment 
Score 
Enrichment p-value 
Olfactory transduction 145.106 9.58E-64 
Cell cycle 51.3958 4.78E-23 
DNA replication 36.5039 1.40E-16 
Neuroactive ligand-receptor interaction 30.9574 3.59E-14 
RNA transport 23.5215 6.09E-11 
Cytokine-cytokine receptor interaction 20.7679 9.56E-10 
Homologous recombination 16.7049 5.56E-08 
Ribosome biogenesis in eukaryotes 15.0612 2.88E-07 
Spliceosome 14.6238 4.46E-07 
Oocyte meiosis 14.3249 6.01E-07 
Pyrimidine metabolism 13.8491 9.67E-07 
Base excision repair 13.1767 1.89E-06 
Nucleotide excision repair 12.2301 4.88E-06 
Mismatch repair 11.6785 8.47E-06 
Chemokine signaling pathway 11.4977 1.02E-05 
Cell adhesion molecules (CAMs) 10.9548 1.75E-05 
Arachidonic acid metabolism 10.4704 2.84E-05 
mRNA surveillance pathway 10.0653 4.25E-05 
Serotonergic synapse 9.03487 0.000119181 
Drug metabolism - cytochrome P450 8.6927 0.000167806 
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Figure 3.8 The B cell receptor signaling pathway was predicted to be the most affected 
pathway from the decreased gene expression seen in ΔBP LEUK compared to ΔB cells: 
The B cell receptor signaling pathway was identified using Partek software from the 
decreased expression of gene in ΔBP LEUK compared to ΔB cells. Genes in blue had 
reduced expression levels in ΔBP LEUK compared to ΔB cells. Genes in black had no 
change in ΔBP LEUK compared to ΔB cells. Notably, most of the genes in this pathway 
were reduced.   
Decreased	  in	  ΔBP	  LEUK	  	  	  	  	  	  	  	  	  	  	  NO	  change	  in	  ΔBP	  LEUK  
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3.8 Confirmation of target genes potentially involved in leukemia  
  RT-qPCR is commonly used to validate microarray data sets to support findings from 
microarray data [83]. RNA from sorted ΔB cells and ΔBP LEUK cells was used in RT-
qPCR to confirm the microarray data.  Ten genes were selected in total for validation, which 
were involved in different pathways that could promote leukemogenesis in our model (see 
discussion).  Four of the selected genes were involved in the B cell receptor signaling 
pathway; Bruton’s tyrosine kinase Btk , B cell linker protein Blnk, Lck/yes-related novel Lyn, 
and guanine nucleotide exchange factor Vav2. Three of the selected genes were from the Wnt 
signaling pathway; lymphoid enhancer binding factor1 Lef1, transcription factor 7 like 2 
Tcf7l2 and  leucine rich repeat containing G protein coupled receptor 5 Lgr5. The remaining 
three genes were for receptors; interleukin seven receptor Il7r, protein tyrosine phosphatase, 
receptor type, C Ptprc which encodes B220, and glutamyl aminopeptidase Enpep which 
encodes Bp-1. Five genes demonstrated an increased expression in ΔBP LEUK cells 
compared to ΔB cells by microarray were also increased by q-PCR; Lef1, Tcf7l2, Lgr5, Il7r, 
Pb-1 (Figure 3.9). Four genes whose expression was decreased in ΔBP LEUK cells 
compared to ΔB cells by microarray were also decreased by q-PCR; Btk, Blnk, Lyn, B220 
(Figure 3.9). Vav2 had no significant change by q-PCR (data not shown).  The q-PCR levels 
of these transcripts concurred with those of the microarray results (Figure 3.10).   
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Fig 3.9 confirmation of target genes potentially involved in leukemia                                 
RT-qPCR was performed on RNA prepared from sorted ΔB cells and ΔBP LEUK cells. 
ΔBP LEUK cells showed an increase in expression of Lef1, Tcf7l2, Lgr5, Il7r, and Enpep  
compared to the ΔB cells. ΔBP LEUK cells showed a decrease in expression of Blnk, Btk, 
Ptprc, and Lyn compared to the ΔB cells. Each result was performed in triplicate and 
significance with P < 0.05 was determined using the Students t-test.  
 
 
44	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  “Volcano plot” of changes in gene expression in splenic ΔBP LEUK cells 
compared to ΔB cells from the microarray experiment.  The nine genes that were 
significantly changed by qPCR  and were concurred with those of the microarray are shown.
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CHAPTER 4: The role of SPIB in ETV6-RUNX1 acute lymphoblastic leukemia 
4.1 Introduction:  
 The chromosomal translocation t(12;21) fuses the ETV6 (TEL) gene to the RUNX1 
(AML1) gene. This is the most common chromosomal alteration in pediatric B cell acute 
lymphoblastic leukemia representing 25% of the cases [68]. ETV6-RUNX1 fusions arise 
prenatally as an initiating event linked to pre-leukemia clonal expansion [68]. The molecular 
mechanism underlying ETV6-RUNX1 function is to interfere with normal RUNX1 function. 
ETV6-RUNX1 represses RUNX1 target genes by the recruitment of nuclear core 
repressor/histone deacetylase complexes [69]. However, little is known about the target genes 
of ETV6-RUNX1 that are involved in leukemogenesis. A recent study with transgenic mice 
carrying the human ETV6-RUNX1 revealed that SPIB had reduced transcript levels [66]. 
Another study with two human leukemia cell lines AT-2 and REH, which express ETV6-
RUNX1, found that SPIB was one of the top genes that were up regulated after knocking 
down the ETV6-RUNX1 fusion protein [67]. These studies lead to our central hypothesis that 
ETV6-RUNX1 functions as an oncogenic driver by repressing SPIB transcription, leading to 
impaired B cell receptor signaling which could cause the block of B cell differentiation 
(Figure 4.1)  
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Figure 4.1 Hypothetical model of ETV6-RUNX1 function in leukemogenesis.  
Boxes represent ETV6, RUNX1, and SPIB genes. Arrowheads indicate transcriptional 
activation. Blunt ends indicate transcriptional repression. 
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4.2 SPIB was one of the top genes that were up regulated after knocking down the 
ETV6-RUNX1 fusion protein.  
   A recent study published by the Grumayer group [67] showed that knocking down the 
ETV6-RUNX1 fusion protein in two human acute lymphoblastic cell lines (AT-2, REH), led 
to the up-regulation of the SPIB transcript levels by 1.6 and 3.59 in REH and AT-2, 
respectively (Figure 4.2). In brief, they used lentiviral shRNA vectors to knock down the 
ETV6-RUNX1 fusion protein in the REH and AT-2 cell lines. The cells that were selected 
for viral integration and stable fusion protein repression had 50-80 % reduction of the ETV6-
RUNX1 fusion protein between different experiments. These cells were used for expression 
profiling; three and two biological replicates were used from independent knockdown 
experiments of the REH and AT-2, respectively. Controls, which were transduced with a 
non-targeting shRNA vector, were used.  Raw data of the Microarray (CEL files) are 
publically available at GEO (www.ncbi.nlm. nih.gov/geo/, accession number GSE29639) [4]. 
   To reproduce the microarray data, CEL files were downloaded and reanalyzed using Partek 
software. The results confirmed that SPIB was one of the top genes that was up regulated 
after knocking down ETV6-RUNX1 in both cell lines. The mean of SPIB expression was 
higher in the reanalyzed data compared to the original study (Figure 4.2), which could be 
explained by the different software used to analyze the data in the original study (R 
program).  Published data were replicated and suggested up-regulation of the SPIB transcript 
levels after knocking down the ETV6-RUNX1 fusion protein.   
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Figure 4.2: SPIB and PU.1 expression levels in ETV6-RUNX1 knocked down cells (E/R 
KD) compared to the control in AT-2 and REH cell lines. A. Data generated from the 
original study showed that SPIB expression was up- regulated by 1.6 and 3.59 in REH and 
AT-2 respectively. There was no significant change in the expression of PU.1. B. Re-
analyzed data showed that SPIB expression level was up regulated by 2.27 and 7.3 in REH 
and AT-2 respectively. There was no significant change in the expression of PU.1.  
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4.3 SPIB expression level was reduced in ETV6-RUNX1 pediatric patient samples 
compared to other subgroups of B cell acute lymphoblastic leukemia patient samples.   
  To investigate whether SPIB expression levels were reduced in human pediatric patients 
who have ETV6-RUNX1 leukemia, microarray data published by Downing’s group was 
reanalyzed [48]. The goals of this study were to use gene expression profiling to accurately 
diagnose and sub-classify pediatric acute leukemias, and to enhance the understanding of the 
underlying biology of each sub-type of acute leukemias. The group collected 132 diagnostic 
bone marrow (BM) aspirates or peripheral blood (PB) samples from pediatric patients with 
different types of acute leukemia (Table 4.1). RNA was extracted from those samples, and 
hybridized to Affymetrix HG-U133A and HG-U133B oligonucleotide microarrays.  
   CEL files of the subgroups of B cell acute lymphoblastic leukemia patient samples were 
downloaded and reanalyzed using Partek software. One-way ANOVA was used to detect the 
differentially expressed genes between the ETV6-RUNX1 pediatric patients and the other 
subgroups of B cell acute lymphoblastic leukemia patient samples (BCR-ABL1, E2A-PBX1, 
MLL and Hyperdiploid >50). The results suggested that SPIB expression was reduced in 
ETV6-RUNX1 compared to MLL, E2A-PBX1, and Hyperdiploid patient samples (Figure 
4.3). The only exception was BCR-ABL, as there was no difference in the SPIB expression 
level between the two groups (data not shown). These results were consistent with the idea 
that SPIB is repressed by ETV6-RUNX1.  
4.4 Five predicted RUNX1 binding sites were located in transcriptionally active sites of 
the SPIB gene 
  Studies illustrated that ETV6-RUNX1 fusion protein can directly bind RUNX1 consensus  
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           Table 4.1: Pediatric acute lymphoblastic patient subgroups [48] 
Samples were collected from acute lymphoblastic leukemia pediatric patients. 
Patients were divided according to the genetic lesions associated with it.  
 
 
 
 
 
 
 
 
 
 
Subgroup Sample number 
BCR-ABL 15 
MLL 20 
E2A-PBX1 18 
Hyperdiploid >50 17 
ETV6-RUNX1 20 
OTHER 28 
T-ALL 14 
Total 132 
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Figure 4.3: SPIB expression levels in ETV6-RUNX1 cells compared to other sub types 
of B-ALL in pediatric patients. SPIB expression levels were reduced by 5.9, 3.5, and 3.2 
fold in ETV6- RUNX1 compared to MLL, E2A-PBX1, and hyperdiploidy respectively. 
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sequence in a target gene, and repress its activation. To determine if SPIB is directly 
regulated by ETV6-RUNX1, computational analysis using Matinspector was done on the 
SPIB gene to predict the RUNX1 binding sites [76]. There were ten predicted RUNX1 
binding sites in the SPIB gene that met a cutoff of .8 of the matrix score. To determine 
whether these binding sites were located in transcriptionally active sites, we crossed 
referenced them to human Encyclopedia of DNA Elements (ENCODE) data [77] . We used 
two data sets from ENCODE to define transcriptionally active sites in the B cell line 
GM12878; DNase I hypersensitivity sites and histone acetylation marker (H3K27AC). Only 
four predicted RUNX1 binding sites were located in transcriptionally active sites (P = 
position; P2, P3, P4, P5) (Figure 4.4). NC is a silent site of the SPIB gene that did not have 
predicted RUNX1 binding sequence, and was used as a negative control for the chromatin 
immunoprecipitation experiments (ChIP) (Figure 4.7). 
  As SPIB is considered to be evolutionary duplicated gene from SPI1, one would expect the 
same regulation pattern to exist.  SPI1 gene is 20 kb apart from its neighboring gene, and has 
upstream regulatory elements [72].  However, this is not true for the SPIB gene. The 
neighboring gene POLD1 is only 800 base pairs apart from the SPIB gene. In addition, the 
POLD1 locus had an intron (intron 20), where blood specific transcription factors were 
bound (e.g. PU.1 and PAX-5) (data not shown). These data suggested that intron 20 of the 
POLD1 gene could serve as a distal enhancer that regulates the SPIB gene. There was only 
one predicted RUNX1 binding site in intron 20 of the POLD1 gene, which was located in a 
transcriptionally active site, henceforth called P1 (Figure 4.4). In summary, the five predicted 
RUNX1 binding sites (P1, P2, P3, P4, P5) that were located in transcriptionally active sites 
could be used to investigate the binding of RUNX1 by ChIP.   
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Figure 4.4: Cross-referenced RUNX1 predicted binding sites on SPIB and POLD1 gene 
to human ENCODE data. The pink peaks represent H3K27AC, which is a histone 
acetylation marker, found near active regulatory elements. The red peaks represent the signal 
of DNase I hypersensitivity at the site. For all the predicted RUNX1 binding sites P1, P2, P3, 
P4 and P5 have high peaks of DNase I and high peaks of H3K27AC markers except for P5. 
NC was chosen in a site that is transcriptionally silent (no H3K27AC peak and DNase I 
peak), and without a RUNX1 binding site. 
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4.5 P3 is highly conserved through evolution. 
 It is accepted that sequences conserved through evolutionary distance, are likely to have 
critical biological function [84]. To determine whether the sequence of the five predicted 
RUNX1 binding sites (P1, P2, P3, P4, P5) are conserved through evolution, a phylogenetic 
analysis was done. Multiple alignments of five mammalian species (rat, mouse, human, cow, 
dog) using Macvector revealed that only P3 was highly conserved between species. P3 is 
located in the first intron of the SPIB gene (Figure 4.5).  
4.6 P3 is highly enriched compared to the negative controls (NC, CRORFII) and the 
other RUNX1 predicted binding sites (P1, P2, P4, P5).  
    To confirm that RUNX1 bound to the five predicted RUNX1 binding sites (P1, P2, P3, P4, 
P5), which were located in transcriptionally active sites, we performed chromatin 
immunoprecipitation (ChIP) using anti-RUNX1 antibody that could detect both RUNX1 and 
ETV6-RUNX1proteins. The REH cell line was used, which was established from a relapsed 
acute leukemia patient. REH expresses both the fusion protein ETV6-RUNX1 and the wild 
type RUNX1 [4]. qPCR was used as the method of choice to analyze ChIP experiments. 
qPCR primers were designed to recognize the RUNX1 predicted binding sites and the 
negative controls. After that, the primers were tested by input DNA prepared from the REH 
cell line to ensure specificity. Results revealed that P3 was highly enriched with 
RUNX1/ETV6-RUNX1 compared to the negative controls (NC, CRORFII) (Figure 4.6) and 
the other RUNX1 binding sites (P1, P2, P4, P5) (Figure 4.7). Collectively, these data suggest 
that RUNX/ETV6-RUNX1 could regulate SPIB expression in pre-B cells by interaction with 
the P3. 
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Figure 4.5: sequence alignment of P3 RUNX1 site in intron one of the SPIB gene in five 
mammalian species. The location of the RUNX1 (aGTGGT) site is highlighted inside a 
square. 
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Figure 4.6: Representative ChIP. Chromatin was prepared from REH cell line and 
immunoprecipitated with anti-RUNX1. Immunoprecipitated DNA was quantified by relative 
qPCR using primers recognizing the RUNX1 binding sites P3 and the negative control 
C4ORFII. Amounts of immunoprecipitated DNA are expressed as percentage of input. 
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Figure 4.7: ChIP analysis. Chromatin was prepared from the REH cell line and 
immunoprecipitated with anti-RUNX1. Immunoprecipitated DNA was quantified by relative 
qPCR using primers recognizing the RUNX1 binding sites P1, P2, P3, P4, P5 and the 
negative controls NC and C4ORFII. Amounts of immunoprecipitated DNA are expressed as 
fold enrichment. Fold enrichment means enrichment using anti-RUNX1 antibody compared 
to nonspecific IgG antibody. The mean ± SD of data from three independent experiments 
with separate chromatin preparations are shown. P < 0.05 was determined using the Students 
t-test.  
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CHAPTER 5: Discussion 
 
5.1 Gene expression analysis of ΔBP LEUK cells suggested increase in cell proliferation, 
and block in B cell differentiation caused by disruption of key pathways.  
    Our lab showed that reduced levels of PU.1 and Spi-B are enough to induce B-ALL in 
mice with 100% incidence [65]. This suggested that PU.1 and Spi-B act as complementary 
tumor suppressors in the B cell linage [65]. The first aim of this study was to explore what 
target genes and pathways were affected by the loss of PU.1 and Spi-B that could explain 
leukemogenesis. This was done by gene expression profiling.  
  Microarray results in general demonstrated high fold changes in differential expressed 
genes (increased-decreased) between ΔBP LEUK cells and ΔB cells. This suggests that PU.1 
is a key transcription factor in leukemogenesis, as using the Spib knock out control ΔB 
eliminated changes due to Spi-B. Mapping those genes to functional groups (pathways), 
showed an increase in the expression of genes involved in cell cycle, cytokine-cytokine 
receptor interaction, and DNA replication. These results may suggest enhanced cell 
proliferation in ΔBP LEUK cells.  Also, block of B cell differentiation in ΔBP LEUK cells 
might be explained with a decrease in expression of genes involved in B cell receptor 
signaling. Key player genes that could explain leukemogenesis from those pathways include 
interleukin 7 receptor Il7r which was highly expressed in ΔBP LEUK cells, Bruton’s 
tyrosine kinase Btk, and B cell linker protein Blnk. Both latter genes were decreased in ΔBP 
LEUK cells and involved in B cell receptor signaling (BCR signaling).  
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 Btk transcripts were reduced by 3.7 fold in ΔBP LEUK cells compared to ΔB cells. 
However, confirmation of this result by q-PCR showed a reduction in Btk expression by 
almost 100-fold change (Figure 3.9, 3.10). In addition, Btk was highly reduced at the protein 
level in ΔBP LEUK cells compared to ΔB cells, which was shown by western blot analysis 
done by other members of the lab (unpublished data). These results confirm what has been 
previously published in the literature that Btk expression requires PU.1[85]. Studies of Btk 
deficient mice showed that Btk has a central role in B cell differentiation [40, 41]. Also, 
studies have illustrated the role of Btk in the progression of pre-B cells to immature B cells. 
Btk – deficient pre-B cells had increased proliferation capacity in response to IL7 [40]. In 
addition, during transition of these Pre-B cells to small resting Pre-B cells, they failed to 
down regulate the metallopeptidase BP-1 and sialoglycoprotein CD43, and had impaired up 
regulation of the CD2 adhesion molecule and IL2R [40]. Interestingly, ΔBP LEUK cells also 
failed to down regulate the BP-1 and CD43, and had increased CD2, which could be 
explained at least partially by the loss of Btk expression. Btk mutations alone do not cause B-
ALL [86]. However, mice with mutations in both Btk and Blnk had pre-B cell leukemia with 
75% incidence rate as compared to 5% in Blnk only deficient mice [86]. In addition, it has 
been reported that BTK had reduced expression levels in childhood acute lymphoblastic 
leukemia [87]. Therefore, loss of PU.1 expression can result in reduced Btk transcript levels 
that may play a role in the block or impairment of B cell differentiation in ΔBP LEUK cells 
in cooperation with other genes such as Blnk.   
   Blnk transcript levels were also reduced by 2.7 fold in ΔBP LEUK cells compared to ΔB 
cells. q-PCR results were concordant with the microarray data (Figure 3.9, 3.10). Recently, 
our lab established that PU.1 and Spi-B are direct activators of Blnk [88]. Blnk is an adaptor 
protein that has a dual function in B cells. It promotes differentiation by transmitting the 
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differentiation signals of the Pre-BCR, and it has negative effects on proliferation by 
blocking IL-7 signaling [89, 90].  There are several mechanisms of how Blnk might down 
regulate IL-7 signaling. First, Blnk can directly bind to JAK3 resulting in uncoupling JAK3 
and IL-7R [91]. Second, Blnk can inhibit the activation of the PI3K-AKT pathway 
downstream of IL-7R signaling [90, 92]. Blnk mutations or reduced expression are associated 
with human B-ALL [47, 93]. Therefore, reduction in the expression of PU.1 and Spi-B will 
result in the reduction of Blnk in ΔBP LEUK cells. This will lead to decreased differentiation 
signals, and increased IL-7 signaling pathways. This might explain the impairment of B cell 
differentiation and enhanced proliferation through increased IL-7R signaling in ΔBP LEUK 
cells.  
   It has been shown that over expression of IL-7 can lead to leukemia in mice [94]. Also, IL-
7R gain of function mutations is associated with pediatric acute lymphoblastic leukemia [95].  
Il7r was highly expressed in ΔBP LEUK cells compared to ΔB cells. q-PCR results were in 
agreement with the microarray results (Figure 3.9, 3.10). In addition, our lab has 
demonstrated that Il-7R signaling pathway through PI3K-AKT is activated, and ΔBP LEUK 
cells can grew indefinitely in response to IL7 cytokine in vitro [88]. These results suggested 
that IL-7 and IL-7R are important in the proliferation of ΔBP LEUK cells.  
    In summary, these results suggest that PU.1 and Spi-B are important transcription factors 
that play a role in the balance between the proliferation and differentiation of B cells by 
activating genes required for BCR signaling that promote differentiation and inhibit 
proliferation.  
     Other candidate genes that could explain the disruption of B cell differentiation in ΔBP 
LEUK cells belong to the Wnt-signaling pathway. Although the Wnt-signaling pathway was 
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not significantly enriched, Lef1 was one of the top 100 genes that was increased by 20 fold in 
ΔBP LEUK cells (Figure 3.9, 3.10).  Knock out studies of Lef1 showed that is required for 
pro-B cell proliferation [96]. On the other hand, overexpression of Lef1 caused a severe 
disruption of normal hematopoietic differentiation leading to B lymphoblastic and acute 
myeloid leukemias [97].  In addition, LEF1 mutations were associated with human ALL [46]. 
Therefore, increased Lef1 expression may contribute to the disruption of B cell development 
in ΔBP LEUK cells. Other candidate genes from the Wnt-signaling pathway included Tcf7l2 
and Lgr5 that were also up regulated in ΔBP LEUK cells, and their expression levels were 
confirmed by q-PCR (Figure 3.9,3.10).  
     Overall, microarray results were consistent with what has been published in the literature 
about the PU.1 target genes[82]. The comparison of the 110 known target genes of PU.1 
revealed that 40% of those genes were reduced in ΔBP LEUK cells (Figure 3.7). There were 
exceptions of 11 genes known to be activated by PU.1 that were up regulated in ΔBP LEUK 
cells. There are two potential explanations for these findings.  First, the activation of certain 
genes such as Cdk6 and Irf4 by PU.1 were shown only in erythroid and myeloid cell types 
respectively, which may refer to the difference in the context of gene regulation between the 
cell types [98, 99]. Second, some genes may require PU.1 for activation but not for continual 
expression, such as Il7r [21]. The Il7r activated during the common lymphoid progenitor 
stage, which is before cre- mediated PU.1 deletion in ΔBP LEUK cells [24, 65]. In addition 
to consistency with the published literature, validation of the expression of selected genes by 
q-PCR showed an agreement in the direction of the fold change except for vav2, which did 
not change significantly (Figure 3.9,3.10). This agreement in the direction of fold change is 
considered enough as microarray technique differs from q-PCR in many aspects such as the 
region of the gene targeted by the microarray probes and the q-PCR primers, and the 
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normalization methods. These all will affect how the results will correlate [83].  
   In summary, ΔBP LEUK cells have reduced expression of key genes involved in BCR 
signaling, which also have been reported in human B-ALL. Although our data does not show 
the effect of loss of Spi-B on gene expression, it is reasonable to conclude that Spi-B will 
affect BCR signaling for the following reasons. First, PU.1 and Spi-B have identical binding 
sites, which suggests that they can trans-activate the same target genes [65]. Second, Spib -/- 
B cells are defective in one or more BCR signaling components, which could be directly 
regulated by Spib [64]. This may indicate that reduced expression or mutations in PU.1 and 
SPIB could play a role in the pathogenesis of human B-ALL through the disruption of BCR 
signaling.  
5.2 Reduced levels of SPIB in childhood ETV6-RUNX1 B cell acute lymphoblastic 
leukemia:  
   Recently, studies have demonstrated that impaired expression of PU.1 and SPIB is 
associated with human B-ALL. Mutations of SPI1 have been reported in relapsed acute 
lymphoblastic leukemia patients [49]. Also, a recent study by the Grumayer group with two 
human leukemia cell lines AT-2 and REH, which express ETV6-RUNX1, suggested that 
SPIB was one of the top genes that were up regulated after knocking down the ETV6-
RUNX1 fusion protein [67]. These studies triggered us to question if ETV6-RUNX1 function 
as an oncogenic driver by repressing SPIB transcription. To confirm what the Grumayer 
group published, re-analysis of the published microarray data was done. The re-analyzed 
results were consistent with what was published in the original paper. SPIB was at the top of 
the gene list that was up regulated after knocking down ETV-RUNX1 protein. PU.1 
transcript levels did not change between the knocked down and the control in either cell lines 
63	  
(Figure 4.2). These results suggested that SPIB but not PU.1 has impaired expression in 
ETV6-RUNX1 leukemia.  This led us to question if this phenomena will be true in actual 
patient samples from pediatric ETV6-RUNX1 leukemia. Re-analysis of the published 
microarray data by the Downing group confirmed the trend of reduced SPIB transcript levels 
in pediatric patients with ETV6-RUNX1 leukemia compared to the other sub-types of B-
ALL (Figure 4.3)[48]. The exception was with BCR-ABL1 leukemia where there was no 
difference in the SPIB expression compared to ETV6-RUNX1 leukemia.  This suggests that 
SPIB transcript levels are also reduced in BCR-ABL1 leukemia. This finding is in agreement 
with what was published by the Muschen group where they showed that SPIB transcript 
levels were reduced in BCR-ABL1 leukemia patients [100]. In summary, these results 
suggest that SPIB is suppressed in ETV6-RUNX1 human leukemia cell lines and pediatric 
patients with this subtype of B-ALL. The next step of this study was to investigate the 
mechanism by which SPIB expression is reduced in ETV6-RUNX1 leukemia.          
5.3 The ETV6-RUNX1 fusion protein could repress SPIB transcription:  
   Previous studies have shown that ETV6-RUNX1 fusion proteins could interact with 
RUNX1 binding sites, which will cause the repression of RUNX1 target genes via the 
recruitment of nuclear core repressor/histone deacetylase complexes [69, 101]. We 
hypothesized that ETV6-RUNX1 would repress SPIB expression by interacting with RUNX1 
binding sites on SPIB. To test this hypothesis we first used computational software 
(MATINSPECTOR) to predict RUNX1 binding sites within the SPIB gene [76]. These sites 
were scanned for transcriptional activation using ENCODE data [77]. Two markers were 
used to define transcriptional active sites in the B cell line GM12878. The first marker was 
DNase I hypersensitivity, and the second marker was histone acetylation modification 
(H3K27AC), which has been shown to distinguish active enhancers from inactive enhancer 
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elements [77, 102].  Only four predicted RUNX1 sites were located in transcriptionally active 
sites (P2, P3, P4, P5) (Figure 4.4). P3 is highly conserved through evolution, suggesting a 
critical biological function (Figure 4.5). P3 was located in the first intron below the 
transcription start site that has been shown to be active in early stages of B cell development 
[103]. This data indicate that we have identified an important enhancer/promoter that could 
be negatively regulated by ETV6-RUNX1 in pre-B ALL cells. In addition to the SPIB locus, 
intron 20 of the POLD1 gene could serve as a distal enhancer that regulates the SPIB gene 
(Figure 4.4). The rationale behind this is that SPIB is thought to be evolutionary duplicated 
from the SPI1 gene[104]. Interestingly, unlike SPIB, SPI1 gene is 20 KB apart from its 
neighboring gene, and has upstream regulatory elements [72]. POLD1 is only 800 base pairs 
apart from the SPIB gene. ChIP experiments showed that P3 was highly enriched with 
RUNX1/ETV6-RUNX1. Therefore, these results indicate that RUNX1/ETV6-RUNX1 could 
regulate SPIB. Future work needs to be done in order to determine whether it is suppressing 
or activating the SPIB gene.  
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5.4 Future directions:  
  This project provided insight into the role of PU.1 and Spi-B as tumor suppressor genes in 
B-ALL in mice. In addition, it specified a mechanism for the impairment of expression of  
SPIB in ETV6-RUNX1 B-ALL. Yet, more work needs to be done to confirm the repression 
function of ETV6-RUNX1 on SPIB and to address the downstream consequences of ETV6-
RUNX1 inhibition of SPIB expression along with the changes induced by other cooperating 
mutations. First, to confirm the repressor function of ETV6-RUNX1, two approaches can be 
used. Knocking down ETV6-RUNX1 can be done to illustrate the up-regulation of SPIB in 
the REH cell line. In addition, direct examination of the repression function of ETV6-RUNX1 
can be done by cloning the region around P3 and ligating it into luciferase reporter vector.  If 
the conclusion from these assays were that ETV6-RUNX1 represses SPIB expression, then it 
would be interesting if we can show that enforced expression of SPIB in the REH cell line 
will promote differentiation and change cell cycle status in the REH cell line. In addition, this 
assay will help in identifying novel target genes that could be regulated by SPIB. Finally, it 
would be interesting if the findings from the REH cell line could be validated in primary 
ETV6-RUNX1 patient samples. This could be done using standard curves to measure the 
transcript levels of SPI1 and SPIB using qPCR. Other techniques could be used. This study is 
expected to lead to a deeper understanding of the underlying biology of leukemogenesis 
caused by the loss of SPIB in ETV6-RUNX1 leukemia patients, hence allow for the 
development new molecular targeted therapies for B-cell leukemia.  
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5.5 Summary and conclusions: 
   In this study, we provide mechanistic evidence to explain how PU.1 and Spi-B could play a 
role in the leukemogenesis of ETV6-RUNX1 B cell leukemia (Figure 5.1).  We tackled this 
question using three approaches. The first approach was to understand how PU.1 and Spi-B 
function as tumor suppressor genes in B cells. A mouse model that conditionally knocked out 
PU.1 in B cells on a Spib-/- background was used. These mice develop B-ALL with 100% 
incidence. Gene expression analysis was used to explore what pathways and target genes 
were affected by the loss of PU.1 and Spi-B. This work identified the B cell receptor-
signaling pathway as the most affected pathway where most of the involved genes had 
reduced expression in ΔBP LEUK cells, which might explain the block in B cell 
differentiation.  The second approach was to measure the SPI1 and SPIB transcript levels by 
re-analyzing published microarray data from the human REH cell line and pediatric patient 
samples, which express the ETV6-RUNX1 fusion. Results from the microarray analysis 
suggested that SPIB is repressed by ETV6-RUNX1. The third approach was to address the 
mechanism of how SPIB is repressed in ETV6-RUNX1 leukemia patients and the human 
REH cell line. Chromatin immunoprecipitation experiments were done using the REH cell 
line to identify putative binding sites of RUNX1. Our findings strongly suggest that SPIB 
expression is reduced in ETV6-RUNX1 leukemia, and it could be repressed by ETV6-
RUNX1 fusion protein. 
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Figure 5.1 hypothetical model of ETV6-RUNX1 function in leukemogenesis.  
Impaired	  BCR	  signaling	  	  
First	  approach:	  using	  the	  mouse	  model	  	  
Second	  and	  third	  approach:	  using	  REH	  human	  cell	  line	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